TD Cowen lowered the firm’s price target on Sage Therapeutics to $24 from $28 and keeps an Outperform rating on the shares. The for noted they announced plans to reorganize its business operations and pipeline priorities to support the planned 4Q launch of Zurzuvae in PPD and prioritize/advance 718 and 324 in clinical studies as well as noting early-stage programs have been paused.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SAGE:
- Sage Therapeutics price target raised to $27 from $24 at Scotiabank
- Sage Therapeutics (NASDAQ:SAGE) Slashes 40% of Positions with Zurzuvae Launch in Mind
- Sage Therapeutics announces changes to leadership team
- Sage Therapeutics announces plans to reorganize business operations
- Sage Therapeutics management to meet with Piper Sandler
